The Immunotherapy Pipeline

Below is a partial list of immunotherapeutic agents under investigation for the treatment of malignant and non-malignant hematologic conditions, including monoclonal antibodies, immune checkpoint inhibitors, and vaccines. Information was gathered from ClinicalTrials.gov, as well as the respective drug manufacturers.

For a comprehensive list of agents being evaluated for these conditions, please consult ClinicalTrials.gov.


Leukemia

Alemtuzumab: a recombinant humanized anti-CD52 monoclonal antibody for the treatment of B-cell CLL (phase II)

Atezolizumab: a programmed death-ligand 1 (PD-L1) blocking antibody for the treatment of relapsed or refractory advanced myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (phase I/II) or high-risk chronic lymphocytic leukemia (CLL; phase II)

Blinatumomab: an anti-CD19/CD3 bispecific T-cell engager antibody for the treatment of relapsed or refractory Ph-positive acute lymphocytic leukemia (ALL; phase II)

CC-122: a pleiotropic pathway modifier for the treatment of CLL/small lymphocytic lymphoma (phase I/II)

Durvalumab: an anti PD-L1 monoclonal antibody for the treatment of previously untreated, higher-risk MDS or older patients with acute myeloid leukemia (phase II)


Myeloma

ALT-803: an interleukin-15 superagonist protein complex for the treatment of relapsed or refractory myeloma (phase I/II)

AMG 420: an anti-BCMA/anti-CD3 bispecific antibody for the treatment of multiple myeloma (phase I)

AUTO2: anti-BCMA/TACI CAR T cells for the treatment of relapsed or refractory multiple myeloma (phase I/II)

BB2121: an anti-BCMA CAR T-cell construct for the treatment of relapsed or refractory myeloma (phase I)

BMS-986016: an anti-LAG-3 monoclonal antibody for the treatment of relapsed or refractory B-cell malignancies
(phase I/II)

CART-138: anti-CD138 CAR T cells for the treatment of relapsed or refractory, CD138-positive myeloma (phase I/II)

CART-BCMA: autologous T cells expressing B-cell maturation antigen (BCMA)–specific CARs with tandem TCR and 4-1BB costimulatory domains for the treatment of relapsed and/or refractory multiple myeloma after autologous hematopoietic cell transplantation or intensive chemotherapy (phase I)

Dendritic cell/myeloma fusion vaccine: a fusion vaccine for the treatment of myeloma after AHCT (phase II)

JNJ-64007957: an anti-BCMA/anti-CD3 bispecific antibody for the treatment of relapsed or refractory multiple myeloma (phase I)

SGN-CD352A: an anti-CD352 antibody-drug conjugate for the treatment of relapsed or refractory multiple myeloma (phase I)


Lymphoma

Avelumab: an anti-PD-L1 antibody for the treatment of diffuse large B-cell lymphoma (DLBCL; phase III) and Hodgkin lymphoma (phase I)

Axicabtagene ciloleucel: anti-CD19 CAR T cells for the treatment of refractory DLBCL (phase I/II), relapsed or refractory indolent non-Hodgkin lymphoma (phase II), or relapsed or refractory mantle cell lymphoma (phase II)

UCART019: anti-CD19 CAR T cells for the treatment of B-cell lymphoma (phase I/II)

Bleeding and Clotting Disorders

BMN 270: a gene therapy using an adeno-associated virus–factor VIII vector for the treatment of severe hemophilia A (phase I/II)

Emicizumab: a recombinant, humanized, bispecific monoclonal antibody for bleeding prophylaxis in children and adolescents with hemophilia A and factor VIII inhibitors (phase III)

Fitusiran: an RNA interference therapy for the treatment of hemophilia A or B with or without inhibitors (phase II) ●

SHARE